Pathologists find cases with variability in intensity and completeness of staining challenging to interpret, and intratumoural heterogeneity is more commonly encountered in cases with 1+ and 2+ HER2 staining, i.e., HER2-low cancers, with up to 86% of 1+ cases showing variable expression of HER2 protein [67]. Here, ERBB2 is linked to cancer.